Dr. Kompella’s laboratory develops nano-scale technologies for delivery of drugs and gene vectors to various compartments of the eye. His laboratory employs supercritical fluid technology for preparing drug delivery systems. The delivery systems are intended for treating various disorders including diabetic retinopathy, age related macular degeneration, and cancers of the eye, and corneal angiogenesis. His recent work has addressed the influence of pigmentation, diabetes mellitus, and choroidal neovascularion on effectiveness of transscleral delivery of drugs to the eye. He and Dr. Petrash are collaborating on a new project to develop nanoparticle formulations for slow sustained release of biotherapeutic proteins in the eye. Dr. Kompella also collaborates with vision scientists at Emory University and University of Nebraska on delivery of growth factors and other therapeutic agents to the eye.